Phase I Trial of GR1803 Injection in Patients With RRMM

NCT07102706 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma (MM)

Interventions

DRUG: GR1803 injection

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.